Welcome to our dedicated page for Generate Biomedicines news (Ticker: GENB), a resource for investors and traders seeking the latest updates and insights on Generate Biomedicines stock.
Generate Biomedicines, Inc. reports news tied to its clinical-stage biotechnology pipeline, generative biology platform, and public-company disclosures. Recurring updates cover financial results, business updates, clinical program progress for GB-0895, GB-4362, and GB-5267, regulatory designations, and collaborations connected to its protein therapeutic candidates.
Company news also includes shareholder voting matters, capital-structure disclosures, and clinical or regulatory disclosures following its transition to a Nasdaq-listed public company.
Generate Biomedicines (NASDAQ: GENB) plans to participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026.
A live webcast and an archived replay are expected to be available on the company’s investor website under Events and Presentations.
Generate Biomedicines (NASDAQ: GENB) reported Q1 2026 results and clinical progress on May 7, 2026. Cash, cash equivalents, and marketable securities totaled $516.6M as of March 31, 2026, reflecting $369.3M net IPO proceeds. Revenue was $7.2M; net loss was $61.7M. SOLAIRIA-1 and SOLAIRIA-2 Phase 3 trials for GB-0895 continue; GB-4362 sites activated with FDA Fast Track designation and mid-2026 dosing expected; GB-5267 first dosing expected in H2 2026. Generate expects cash to fund operations into H1 2028 and may require additional capital for longer-term operations.
Generate Biomedicines (Nasdaq: GENB) priced an initial public offering of 25,000,000 shares at $16.00 per share, implying gross proceeds of $400 million before underwriting discounts and offering expenses. The underwriters have a 30‑day option for an additional 3,750,000 shares.
Generate's common stock is expected to begin trading on the Nasdaq Global Select Market on February 27, 2026, and the offering is expected to close on March 2, 2026, subject to customary closing conditions. The SEC declared the registration effective on February 26, 2026.